Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
Quiz
Tislelizumab Plus HMA and CAG for Relapsed/Refractory AML
06/16/2025
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial...
06/16/2025
Oncology
Quiz
Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML
09/25/2024
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to...
09/25/2024
Oncology
Quiz
Treating Acute Myeloid Leukemia With Aspacytarabine
03/05/2024
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine...
03/05/2024
Oncology
Quiz
Fractionated Vs Single-Dose Gemtuzumab Ozogamicin Among Older Patients With AML
02/15/2024
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated...
02/15/2024
Oncology
Quiz
Humanized Bispecific Antibody Vibecotamab for R/R AML
02/07/2024
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering...
02/07/2024
Oncology
Quiz
Treating TP53-Mutated AML With Venetoclax Plus HMA Therapy
01/10/2024
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to...
01/10/2024
Oncology
Quiz
Fludarabine-Based Regimen Vs Standard 7 + 3 Regimen for WT1-Mutated AML
12/09/2023
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did...
12/09/2023
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use